Over the past five years, shares of Medtronic (MDT) have slumped more than 30%, weighed down by rising costs, supply chain bottlenecks, quality control issues, and mounting competitive pressure in surgical robotics. Even after factoring in reinvested dividends, the total return has been negative — a painful stretch for a stock once considered a reliable blue chip.
Yet Wall Street remains firmly in the bull camp. The average analyst price target stands at $98.44, while the most optimistic target reaches $121. With the stock currently trading around $86, hitting that high-end target implies a potential upside of more than 40% before the year is out. The case for such a rebound is growing stronger, backed by improving financials and a clear strategic pivot.
Medtronic delivered a standout performance in fiscal 2026, which ended this April. Revenue climbed 8.4% to $36.4 billion, with organic growth of 5.8% marking the fastest top-line expansion in ten years. From fiscal 2026 through fiscal 2029, analysts project revenue and earnings per share to grow at compound annual rates of 5% and 13%, respectively.
A new generation of products is driving the momentum. The Affera pulsed field ablation system for atrial fibrillation, the Symplicity Spyral renal denervation system for treatment-resistant hypertension, and the Hugo robotic-assisted surgery platform are emerging as key growth engines. Meanwhile, the company is embedding artificial intelligence across its endoscopy module and spinal surgical planning products, pushing deeper into smart surgery.
In March, Medtronic completed the spin-off of its diabetes unit, which now trades independently under the name MiniMed. The separation is designed to streamline operations, allowing management to channel resources toward the higher-margin cardiovascular and neuroscience portfolios. The restructuring, combined with the expanding robotics and AI pipeline, is expected to gradually improve free cash flow generation.
Free cash flow in fiscal 2026 rose 4.6% to $5.43 billion. Dividend payments consumed $3.64 billion of that total, leaving ample room for reinvestment and further shareholder returns. Over the past five years, the company has also repurchased nearly 5% of its outstanding shares.
The dividend story is a standout feature. At the current price, the forward dividend yield sits at roughly 3.4%. In June, Medtronic raised its payout for the 49th consecutive year. One more increase would push the streak to 50 years, officially elevating the company into the elite Dividend Kings club — a milestone that carries significant weight with income-focused investors.
Valuation adds another layer of comfort. Medtronic trades at approximately 15 times forward earnings, a steep discount to the S&P 500’s multiple of 29 and to Intuitive Surgical’s 32 times forward earnings. The implication is clear: the stock does not require accelerating growth to re-rate higher. Simply delivering on conservative analyst estimates should be enough to lift the share price as the market begins to price it as a steady dividend compounder rather than a troubled device maker.
Supply chain headwinds and quality control concerns have not fully disappeared, and the long-term overhang from GLP-1 weight-loss drugs on surgical volumes still needs time to play out. But the picture is shifting. Accelerating revenue, a business focused on high-margin segments, robust free cash flow, a dividend track record on the cusp of a historic milestone, and deeply discounted valuation together form the outline of a turnaround. If these catalysts continue to materialize, Medtronic may finally be poised to reclaim its place as a dividend stalwart — and reward patient investors along the way.
